Tivozanib (Fotivda)

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from Tivozanib (AV-951))
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.

Diseases for which it is used

History of changes in FDA approval

  • 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Also known as

  • Code name: AV-951
  • Brand name: Fotivda